Leonard Zehr, Author at BioTuesdays

Feature

Chi-Med transforming into fully integrated pharma

By Len Zehrs After 17 years of blistering growth in China, Hutchison China Meditech (Chi-Med) (AIM, NASDAQ:HCM) is taking center stage as a global drug innovator, with a fully integrated pipeline approaching regulatory...

January 9, 2018

Developments

Eiger completes enrollment in Phase 2 ULTRA study

Eiger BioPharmaceuticals (NASDAQ:EIGR) completed enrollment of the Phase 2 ULTRA study designed to evaluate the effects of ubenimex in patients with primary and secondary lymphedema of the lower limbs. A total of 54...

January 4, 2018

Executive Moves

Eiger BioPharma names Dr. David Apelian as COO, EMO

Eiger BioPharmaceuticals (NASDAQ:EIGR) appointed Dr. David Apelian as chief operating officer and executive medical officer.

January 3, 2018

Feature

IntelGenx to regain WW rights to commercialize Rizaport

By Len Zehrs Early in January, IntelGenx (OTCQX:IGXT; TSXV:IGX) will regain exclusive worldwide rights to develop and commercialize its Rizaport oral thin-film treatment of acute migraines. The move follows a decision...

December 19, 2017

Feature

Soricimed planning to initiate Phase 1b/2a solid tumor trial in Q2

By Len Zehrs Closely-held Soricimed Biopharma expects to initiate in the second quarter of 2018 a Phase 1b/2a clinical trial with its SOR-C13 drug candidate in patients with prostate cancer, including men who have...

December 12, 2017

Feature

Crescita targeting $50-million in revenue in 5 years

By Len Zehrs Crescita Therapeutics (TSX:CTX), is aiming to be a $50-million commercial dermatology company in the next five years, with a portfolio of non-prescription skincare products and prescription drug products...

December 5, 2017

Feature

BioLight dry eye subsidiary approaching CE Mark filing, U.S. pivotal trial

By Len Zehrs DiagnosTear, the dry eye diagnostic subsidiary of BioLight Life Sciences (TASE:BOLT), hopes to file by the end of 2017 for CE Mark approval in Europe and begin a pivotal trial in the U.S. in mid-2018 with...

November 28, 2017

Feature

GeNeuro pioneering HERVs against neurodegenerative and autoimmune diseases

By Len Zehrs Swiss-based GeNeuro (Euronext Paris: CH0308403085 – GNRO) is leveraging the biology of human endogenous retroviruses (HERVs) to stop the causes of neurodegenerative and autoimmune diseases, such as multiple...

November 21, 2017

Feature

Marrone Bio focused on 2 near-term pest management products

By Len Zehrs Marrone Bio Innovations (NASDAQ:MBII), which recently received EPA approval for its newest biological fungicide, Stargus, is focused on commercializing its two near-term products: a new herbicide for...

November 14, 2017

Feature

Mazor’s odyssey to spine robotic surgery leader

By Len Zehr Since its founding 15 years ago, Mazor Robotics (NASDAQ, TASE:MZOR) has overcome challenges typical to medical device startups to become the leader and possibly the standard of care in spine robotics surgery...

October 31, 2017

Author - Leonard Zehr

Chi-Med transforming into fully integrated pharma

Eiger completes enrollment in Phase 2 ULTRA study

Eiger BioPharma names Dr. David Apelian as COO, EMO

IntelGenx to regain WW rights to commercialize Rizaport

Soricimed planning to initiate Phase 1b/2a solid tumor trial in Q2

Crescita targeting $50-million in revenue in 5 years

BioLight dry eye subsidiary approaching CE Mark filing, U.S. pivotal trial

GeNeuro pioneering HERVs against neurodegenerative and autoimmune diseases

Marrone Bio focused on 2 near-term pest management products

Mazor’s odyssey to spine robotic surgery leader

General

More